BRIEF CURRICULUM VITAE

Name:  Renard, Eric, Marcel, René

Date and Place of Birth:  January 25, 1960, in Roubaix (Nord, France)

Citizenship:  French

Business Address:  Department of Endocrinology, Diabetes and Nutrition,
Lapeyronie University Hospital;  F34295 MONTELLIER cedex, France

Present Position : Professor of Endocrinology, Diabetes and Metabolism, Montpellier Medical School, Montpellier I University; Head of the Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, France.

Relevant Experience/Career :

• Doctorate in Medicine (MD), Montpellier I University, 1987.
• Specialist in Endocrinology & Metabolic Diseases, Montpellier I University, 1988.
• National Diploma of Specialist in Nephrology, 1989.
• Diploma of Advanced Studies in Food Science & Nutrition, Montpellier I University, 1989.
• Research Fellowship (Arthur Sachs Scholarship), Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA, 1992.
• PhD in Biochemistry & Molecular Biology, Montpellier I University, 1995.
• Ability to Research Direction, Montpellier I University, 1996.
• Medical Director of Clinical Research at Montpellier University Hospital, since 2008.
• Head of Clinical Investigation Center (CIC) INSERM 1001 (2010-2013), INSERM 1411, since 2014.
• Team leader on the topic: ‘Determinants and correction of insulin secretion loss in diabetes’ at Institute of Functional Genomics (UMR CNRS 5302/INSERM U661/UM1/UM2), Montpellier, France, since 2012.

Publications on Implanted Pumps & Intra-peritoneal Insulin Delivery:

1. E. Renard, D. Lauton, C. Bonifacj, G. Costalat, D. Jacques, J. Bringer, C. Jaffiol. Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps. Diabete Metab 1993, 19 : 364-371.
2. C. Broussolle, N. Jeandidier, H. Hanaire-Broutin For The Evadiac Study Group (J. P. Tauber, M. Pinget, J. Bringer, E. Renard, V. Lassmann-Vague, D. Raccah, P. Vague, P. Drouin, O. Ziegler, B. Guerci, J. L. Selam, M. J. Haardt, G. Slama, F. Gilly). French multicentre experience with implantable insulin pumps. Lancet 1994, 343 : 514-515.
3. E. Renard, J. Bringer, D. Jacques-Apostol, D. Lauton, C. Mestre, G. Costalat, C. Jaffiol. Complications of the pump-pocket may represent a significant cause of incidents with implanted systems for intraperitoneal insulin delivery. Diabetes Care 1994, 17 : 1064-1066.
4. E. Renard, P. Baldet, M. C. Picot, D. Jacques-Apostol, D. Lauton, G. Costalat, J. Bringer, C. Jaffiol. Catheter complications with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors and obstructing materials. Diabetes Care 1995, 18 : 300-306.
5. H. Hanaire-Broutin, C. Broussolle, N. Jeandidier, E. Renard, B. Guerci, M. J. Haardt, V. Lassmann-Vague For The Evadiac Study Group. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in insulin dependent diabetes: multicenter study. Diabetes Care, 1995 18: 388-392.
6. E. Renard, S. Bouteleau, D. Jacques-Apostol, D. Lauton, F. Boulet-Gibert, G. Costalat, J. Bringer, C. Jaffiol. Insulin underdelivery from implanted pumps using peritoneal route : determinant role of insulin-pump compatibility. Diabetes Care 19 : 812-817, 1996.
7. N. Jeandidier, J. L. Selam, E. Renard, B. Guerci, V. Lassmann-Vague, L. Rocher, H. Hanaire-Broutin, For The Evadiac Study Group. Decreased severe hypoglycaemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Diabetes Care 19 : 780, 1996.
8. M. Scavini, L. Galli, S. Reich, R.P. Eaton, M.A. Charles, F.L. Dunn, The Implantable Insulin Pump Trial Study Group (including E. Renard). Catheter survival during long-term insulin therapy with an implanted programmable pump. Diabetes Care 20 : 610-613, 1997.
9. V. Lassmann-Vague, B. Guerci, H. Hanaire-Broutin, M. Pinget, E. Renard, J.L. Selam, P. Vague on behalf of the EVADIAC Group. Use of implantable insulin pumps: The EVADIAC position. Diabete Metab 23: 234-250, 1997.
10. P. Belicar, V. Lassmann-Vague, The EVADIAC Study Group (including E. Renard). Local adverse avents associated with long-term treatment by implantable insulin pumps: The French EVADIAC Study Group experience. Diabetes Care 21: 325-326, 1998.
11. P. Belicar, N. Jeandidier, E. Renard, S. Boivin, P. Gross, M. Pinget, V. Lassmann-Vague. Implanted insulin pump may represent a chance for young women with unstable type 1 diabetes to give birth. Diabetes Care 22 : 1001-1002, 1999.
12. E. Renard, C. Souche, D. Jacques-Apostol, D. Lauton, F. Gibert-Boulet, G. Costalat, J. Bringer, C. Jaffiol. Improved stability of insulin delivery from implanted pumps using a new preparation process for infused insulin. Diabetes Care 22 : 1371-1372, 1999.
13. H. Gin, V. Melki, B. Guerci, B. Catargi, EVADIAC Study Group (including E. Renard). Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump: the EVADIAC experience. Diabetes Care 24 : 175, 2001.
14. E. Renard, T. Rostane, C. Carriere, H. Marchandin, D. Jacques-Apostol, D. Lauton, F. Gibert-Boulet, J. Bringer. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. Diabetes Metab, 27: 62-65, 2001.
15. B. Catargi, L. Meyer, V. Melki, E. Renard, N. Jeandidier, for the EVADIAC Study Group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21Ph insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab 28: 133-137, 2002.
16. E. Renard, D. Apostol, D. Lauton, F. Boulet, J. Bringer. Quality of life in diabetic patients treated by insulin pumps. QoL Newsletter 28 : 11-13, 2002.
17. E. Renard. Implantable closed loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol 2: 708-716, 2002.
18. H Gin, E Renard, V Melki, S Boivin, P Schaepelinck-Belicar, B Guerci, JL Selam, JM Brun, JP Riveline, B Estour, B Catargi, and the EVADIAC Study Group. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab 29: 602-7, 2003.
19. E Renard, I Raingeard, G Costalat, D Apostol, D Lauton, F Boulet, J Bringer. Aseptic peritonitis revealed through recurrent catheter obstructions in type 1 diabetic patients treated with continuous peritoneal insulin infusion. Diabetes Care 27 : 276-7, 2004.
20. E Renard. Implantable insulin delivery pumps. Min Invas Ther & Allied Technol 13: 328-335, 2004.
21. JP Riveline, MC Vantyghem, C Fermon, C Brunet, JF Gautier, E Renard, G Charpentier. Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients. Diabetes Metab 31 : 496-8, 2005.
22. Baillot-Rudoni S, Apostol D, Vaillant G, Brun JM, Renard E, on behalf of the EVADIAC study group. Implantable pump therapy restores metabolic control and quality of life in type 1 diabetic patients with Buschke’s non systemic scleroderma. Diabetes Care 29:1710, 2006.
23. Duraitre-Patouraux L, Riveline JP, Renard E, Melki V, Belicar-Schaepelynck P, Selam JL, Guerci B, Millot L, Brun JM, Fermon C, Catargi B, Gin H, Jeandidier N, Lejeune PJ, Lassman-Vague V.  Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study. Diabetes Metab 32: 427-32, 2006.
24. E Renard, G Costalat, H Chevassus, J Bringer. Artificial beta cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 32: 497-502, 2006.
25. E Renard, G Costalat, H Chevassus, J Bringer. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract 74 Suppl 2: S173-7, 2006.
26. E Renard, P Schaepelynck-Belicar on behalf of the EVADIAC group. Implantable insulin pumps: a position statement about their clinical use. Diabetes Metab 33: 158-66, 2007.
27. Renard E. Clinical experience with an implanted closed-loop insulin delivery system. Arq Bras Endocrinol Metabol, 52: 349-54, 2008.
28. Renard E. Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons. J Diabetes Sci Technol 2:735-8, 2008.
29. R.P. Radermecker, E. Renard, A. J. Scheen. Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab Res Rev 2: 491-501, 2009.
30. Liebl A, Hoogma R, Renard E, Geelhoed-Duijvestijn PHLM, Klein E, Diglas J, Kessler L, Melki V, Diem P, Brun JM, Schaepelynck-Bélicar P, Frei T, For the European DiaPort Study Group. Reduction of severe hypoglycaemia with continuous intraperitoneal insulin infusion in Type 1 diabetic patients unsuccessfully treated by continuous subcutaneous insulin infusion. Diabetes Obes Metab 11:1001-8, 2009.
31. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 33, 121-7, 2010.
32. Schaepelynck P, Renard E, Jeandidier N, Hanaire H, Fermon C, Rudoni S, Catargi B, Riveline JP, Guerci B, Millot L, Martin JF, Sola On Behalf Of The Evadiac Group A. A Recent Survey Confirms the Efficacy and the Safety of Implanted Insulin Pumps During Long-Term Use in Poorly Controlled Type 1 Diabetes Patients. Diabetes Technol Ther 13: 657-60, 2011.
33. Spaan NA, Teplova AE, Renard E, Spaan JAE. Implantable insulin pumps: an effective option with restricted dissemination. Lancet Diabetes Endocrinol 2: 358-60, 2014.
34. Schaepelynck P, Riveline JP, Renard E, Hanaire H, Guerci B, Baillot-Rudoni S, Sola-Gazagnes A, Catargi B, Fontaine P, Millot L, Martin JF, Tachouaft H, Jeandidier N, for the EVADIAC group. Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes. Diabetes Technol Ther 16(9):582-9, 2014.

Other Recent Publications (2014-2016):

1. Maïmoun L, Guillaume S, Lefebvre P, Philibert P, Bertet H, Picot MC, Gaspari L, Paris F, Courtet P, Thomas E, Mariano-Goulart D, Bringer J, Renard E, Sultan C. Role of Sclerostin and Dickkopf-1 in the Dramatic Alteration in Bone Mass Acquisition in Adolescents and Young Women With Recent Anorexia Nervosa. J Clin Endocrinol Metab 99:E582-90, 2014.
2. Del Favero S, Bruttomesso D, Di Palma F, Lanzola G, Visentin R, Filippi A, Scotton R, Toffanin C, Messori M, Scarpellini S, Keith-Hynes P, Kovatchev BP, DeVries JH, Renard E, Magni L, Avogaro A, Cobelli C, on behalf of the AP@home consortium. First use of model predictive control in outpatient wearable artificial pancreas. Diabetes Care 37: 1212-15, 2014.
3. Place J, Farret A, Del Favero S, Bruttomesso D, Renard E. Assessment of Patient Perceptions About Web Telemonitoring Applied to Artificial Pancreas Use at Home. J Diabetes Sci Technol 8:225-229, 2014.
4. Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Mize LB, Farret A, Place J, Bruttomesso D, Del Favero S, Boscari F, Galasso S, Avogaro A, Magni L, Di Palma F, Toffanin C, Messori M, Dassau E, Doyle FJ III. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 37: 1789-96, 2014.
5. Zisser H, Renard E, Kovatchev B, Cobelli C, Avogaro A, Nimri R, Buckingham BA, Chase HP, Doyle III FJ, Lum J, Calhoun P, Kollman C, Dassau E, Farret A, Place J, Breton M, Dalla Man C, Del Favero S, Bruttomesso D, Filippi A, Scotton R, Magni L, Toffanin C, Raimondo DM, De Nicolao G, Phillip M, Atlas E, Muller I, Miller S, Beck RW for the Control to Range Study Group. Multi-center Closed-Loop Insulin Delivery Study Identifies Challenges for Keeping Blood Glucose in a Safe Range by a Control Algorithm in Adults and Adolescents with Type 1 Diabetes From Various Sites. Diabetes Technol Ther 16(10):613-22, 2014.
6. Renard E, Boizel R. Comments on Patel et al.’s “Randomized Trial of Infusion Set Function: Steel Versus Teflon”: Early Catheter Failures May Differ According to Teflon Catheter Model. Diabetes Technol Ther 16: 545-6, 2014.
7. Cobelli C, Renard E, Kovatchev B. The artificial pancreas: a digital-age treatment for diabetes. Lancet Diabetes Endocrinol 2(9):679-81, 2014.
8. Borot S, Franc S, Cristante J, Penfornis A, Benhamou PY, Guerci B, Hanaire H, Renard E, Reznik Y, Simon C, Charpentier G; on behalf of the Diabeloop Study Group. Accuracy of a New Patch Pump Based on a Microelectromechanical System (MEMS) Compared to Other Commercially Available Insulin Pumps: Results of the First In Vitro and In Vivo Studies. J Diabetes Sci Technol 8(6):1133-41, 2014.
9. Chase HP, Doyle FJ 3rd, Zisser H, Renard E, Nimri R, Cobelli C, Buckingham BA, Maahs DM, Anderson S, Magni L, Lum J, Calhoun P, Kollman C, Beck RW. Multicenter Closed-Loop/Hybrid Meal Bolus Insulin Delivery with Type 1 Diabetes. Diabetes Technol Ther 16(10):623-32, 2014.
10. Kirchsteiger H, Zaccarian L, Renard E, Del Re L. LMI-based approaches for the calibration of continuous glucose measurement sensors. IEEE J Biomed Health Inform 19: 1697-706, 2015.
11. Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, D’souza DN, Rees TM. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart. J Diabetes 7: 270-8, 2015.
12. Kropff J, Bruttomesso D, Doll W, Farret A, Galasso S, Luijf YM, Mader JK, Place J, Boscari F, Pieber TR, Renard E, DeVries JH. Accuracy of two Continuous Glucose Monitoring (CGM) systems; a direct comparison in clinical research centre and daily life conditions. Diabetes Obes Metab 17: 343-9, 2015.
13. Del Favero S, Place J, Kropff J, Messori M, Keith-Hynes P, Visentin R, Monaro M, Galasso S, Boscari F, Toffanin C, Di Palma F, Lanzola G, Scarpellini S, Farret A, Kovatchev B, Avogaro A, Bruttomesso D, Magni L, DeVries JH, Cobelli C, Renard E, on behalf of the AP@home Consortium. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. Diabetes Obes Metab 17: 468-76, 2015.
14. Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev 32: 21-39, 2016.
15. Courbet A, Endy D, Renard E, Molina F, Bonnet J. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. Sci Transl Med 27; 7(289): 289ra83, 2015.
16. Renard E. Does A1c have to change for hypoglycemia reduction? Diabetes Technol Ther 17: 527-9, 2015.
17. Blain H, Rambourg P, Le Quellec A, Ayach L, Biboulet P, Bismuth M, Blain A, Boulenger JP, Celton B, Combe B, Dauvilliers Y, Davy JM, Geny C, Hemmi P, Hillaire-Buys D, Jalabert A, Jung B, Leclercq F, Léglise MS, Morel J, Mourad G, Ponrouch MP, Puisieux F, Quantin X, Quéré I, Renard E, Ribstein J, Roch-Torreilles I, Rolland Y, Rosant D, Terminet A, Thuret R, Villiet M, Deshormières N, Bourret R, Bousquet J, Jonquet O, Millat B; Groupe de travail CHU de Montpellier – MACVIA-LR. [Appropriate medication prescribing in older people]. Rev Med Interne 36: 677-89, 2015.
18. Joubert M, Baillot-Rudoni S, Catargi B, Charpentier G, Esvant A, Franc S, Guerci B, Guilhem I, Melki V, Merlen E, Penfornis A, Renard E, Riveline JP, Schaepelynck P, Sola-Gazagnes A, Hanaire H; Société Francophone du Diabète (SFD); Société Française d’Endocrinologie (SFE); EVAluation dans le Diabète des Implants ACtifs Group (EVADIAC). Indication, organization, practical implementation and interpretation guidelines for retrospective CGM recording: A French position statement. Diabetes Metab 41: 498-508, 2015.
19. Maïmoun L, Guillaume S, Lefebvre P, Philibert P, Bertet H, Picot MC, Courtet P, Mariano-Goulart D,Renard E, Sultan C. Is Serum Serotonin Involved in the Bone Loss of Young Females with Anorexia Nervosa? Horm Metab Res. 2015 Sep 29. [Epub ahead of print]
20. Diouri O, Place J, Traverso M, Georgescu V, Picot MC, Renard E. Development of a Smartphone Application to Capture Carbohydrate, Lipid, and Protein Contents of Daily Food: Need for Integration in Artificial Pancreas for Patients With Type 1 Diabetes? J Diabetes Sci Technol 9: 1170-4, 2015.
21. Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, Messori M, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Magni P, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Cobelli C, DeVries JH, Renard E, Magni L; AP@home consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3: 939-47, 2015.
22. Ben Brahim N, Place J, Renard E, Breton MD. Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes. J Diabetes Sci Technol 9: 1185-91, 2015.
23. Maïmoun L, Guillaume S, Lefebvre P, Philibert P, Bertet H, Picot MC, Gaspari L, Paris F, Seneque M, Dupuys AM, Courtet P, Thomas E, Mariano-Goulart D, Bringer J, Renard E, Sultan C. Evidence of a link between resting energy expenditure and bone remodelling, glucose homeostasis and adipokine variations in adolescent girls with anorexia nervosa. Osteoporos Int 27: 135-46, 2016.
24. Renard E. Can Diabetes Management Be Done Effectively Through the Cloud? Diabetes Technol Ther 2016 Jan 11. [Epub ahead of print]
25. Varin EM, Wojtusciszyn A, Broca C, Muller D, Ravier MA, Ceppo F, Renard E, Tanti JF, Dalle S. Inhibition of the MAP3 kinase Tpl2 protects rodent and human β-cells from apoptosis and dysfunction induced by cytokines and enhances anti-inflammatory actions of exendin-4. Cell Death Dis 2016 Jan 21; 7: e2065.
26. Stacey M. Anderson, Dan Raghinaru, Jordan E. Pinsker, Federico Boscari, Eric Renard, Bruce A. Buckingham, Revital Nimri, Francis J. Doyle III, Sue A. Brown, Patrick Keith-Hynes, Marc D. Breton, Daniel Chernavvsky, Wendy C. Bevier, Paige K. Bradley, Daniela Bruttomesso, Simone Del Favero, Roberta Calore, Claudio Cobelli, Angelo Avogaro, Anne Farret, Jerome Place, Trang T. Ly, Satya Shanmugham, Moshe Phillip, Eyal Dassau, Isuru S. Dasanayake,Craig Kollman, John W. Lum, Roy W. Beck, Boris Kovatchev, and for the Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care 39 : 1143-50, 2016.
27. Renard E, Farret A, Kropff J, Bruttomesso D, Messori M, Place J, Visentin R, Calore R, Toffanin C, Di Palma F, Lanzola G, Magni P, Boscari F, Galasso S, Avogaro A, Keith-Hynes P, Kovatchev B, Del Favero S, Cobelli C, Magni L, DeVries JH; AP@home Consortium. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. Diabetes Care 39: 1151-60, 2016.
28. Maahs DM, Buckingham BA, Castle JR, Cinar A, Damiano ER, Dassau E, DeVries JH, Doyle FJ 3rd, Griffen SC, Haidar A, Heinemann L, Hovorka R, Jones TW, Kollman C, Kovatchev B, Levy BL, Nimri R, O’Neal DN, Philip M, Renard E, Russell SJ, Weinzimer SA, Zisser H, Lum JW. Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care 39: 1175-9, 2016.
29. Courbet A, Renard E, Molina F. Bringing next-generation diagnostics to the clinic through synthetic biology. EMBO Mol Med 8: 987-91, 2016.
30. Tkachenko P, Kriukova G, Aleksandrova M, Chertov O, Renard E, Pereverzyev SV. Prediction of nocturnal hypoglycemia by an aggregation of previously known prediction approaches: proof of concept for clinical application. Comput Methods Programs Biomed 134: 179-86, 2016.
31. Lamy PJ, Sault C, Renard E. High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report. Ann Biol Clin (Paris), 74:490-4, 2016.
32. Deiss D, Adolfsson P, Zomeren MA, Bolli GB, Charpentier G, Cobelli C, Danne T, Girelli A, Mueller H, Verderese CA, Renard E. Insulin Infusion Set Use: European Perspectives and Recommendations. Diabetes Technol Ther 18: 517-24, 2016.
33. Sampath S, Tkachenko P, Renard E, Pereverzyev SV. Glycemic control indices and their aggregation in the prediction of nocturnal hypoglycemia from intermittent blood glucose measurements. J Diabetes Sci Technol 10:1245-1250, 2016.
34. Kropff J, DeJong J, Del Favero S, Place J, Messori M, Coestier B, Farret A, Boscari F, Galasso S, Avogaro A, Bruttomesso D, Cobelli C, Renard E, Magni L, DeVries JH; AP@home consortium. Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial. Diabet Med 2016 Oct 1.
35. Guillaume S, Jaussent I, Maimoun L, Ryst A, Seneque M, Villain L, Hamroun D, Lefebvre P, Renard E, Courtet P. Associations between adverse childhood experiences and clinical characteristics of eating disorders. Sci Rep 6: 35761, 2016.

Distinctions/Honours:

Fellow of the Royal College of Physicians of Edinbugh (FRCPEdin), since 2011.